DE69309487T2 - Peripheralisierung hämatopoietischer stammzellen - Google Patents

Peripheralisierung hämatopoietischer stammzellen

Info

Publication number
DE69309487T2
DE69309487T2 DE69309487T DE69309487T DE69309487T2 DE 69309487 T2 DE69309487 T2 DE 69309487T2 DE 69309487 T DE69309487 T DE 69309487T DE 69309487 T DE69309487 T DE 69309487T DE 69309487 T2 DE69309487 T2 DE 69309487T2
Authority
DE
Germany
Prior art keywords
peripheralization
stem cells
hematopoietic stem
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69309487T
Other languages
English (en)
Other versions
DE69309487D1 (de
Inventor
Thalia Papayannopoulou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25525430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69309487(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Washington filed Critical University of Washington
Publication of DE69309487D1 publication Critical patent/DE69309487D1/de
Application granted granted Critical
Publication of DE69309487T2 publication Critical patent/DE69309487T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
DE69309487T 1992-11-13 1993-11-15 Peripheralisierung hämatopoietischer stammzellen Expired - Lifetime DE69309487T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97770292A 1992-11-13 1992-11-13
PCT/US1993/011060 WO1994011027A1 (en) 1992-11-13 1993-11-15 Peripheralization of hematopoietic stem cells

Publications (2)

Publication Number Publication Date
DE69309487D1 DE69309487D1 (de) 1997-05-07
DE69309487T2 true DE69309487T2 (de) 1997-10-23

Family

ID=25525430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309487T Expired - Lifetime DE69309487T2 (de) 1992-11-13 1993-11-15 Peripheralisierung hämatopoietischer stammzellen

Country Status (11)

Country Link
US (4) USRE40811E1 (de)
EP (1) EP0670735B1 (de)
JP (2) JP3731892B2 (de)
AT (1) ATE150975T1 (de)
AU (1) AU689454B2 (de)
CA (1) CA2148712C (de)
DE (1) DE69309487T2 (de)
DK (1) DK0670735T3 (de)
ES (1) ES2102196T3 (de)
GR (1) GR3023975T3 (de)
WO (1) WO1994011027A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670735B1 (de) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralisierung hämatopoietischer stammzellen
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
CA2155303C (en) * 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
US20010038834A1 (en) * 1998-01-26 2001-11-08 Gary Balian Bone cancer therapy
PL203114B1 (pl) 1998-09-14 2009-08-31 Regents Board Of Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7838539B2 (en) * 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
CA2384948C (en) * 1999-09-14 2013-07-16 Biogen, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
WO2002037968A1 (en) * 2000-11-10 2002-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US7994144B2 (en) * 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
KR100996378B1 (ko) 2001-07-31 2010-11-25 아노르메드 인코포레이티드 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US20040258673A1 (en) * 2003-04-03 2004-12-23 Hirose Thomas Gordon Elective collection and banking of autologous peripheral blood stem cells
JP2007509042A (ja) * 2003-09-29 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 造血前駆細胞の接着、分化および遊走を変化させるための方法
WO2005113749A2 (en) 2004-05-14 2005-12-01 Becton, Dickinson And Company Stem cell populations and methods of use
CN1993460A (zh) * 2004-07-12 2007-07-04 索林集团意大利有限公司 用于培养人细胞的装置和方法
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1827491A4 (de) * 2004-11-19 2010-07-14 Biogen Idec Inc Behandlung von multipler sklerose
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
LT2558499T (lt) 2010-04-16 2017-07-25 Biogen Ma Inc. Antikūnai prieš vla-4
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (de) 1988-02-26 1990-06-20 Dana Farber Cancer Institute VLA-Proteine
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
ES2102009T5 (es) 1992-01-13 2004-12-16 Biogen Inc Tratamiento para el asma.
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (de) 1992-02-12 1997-04-16 Biogen, Inc. Behandlung für entzündungserkrankung des darmes
EP0670735B1 (de) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralisierung hämatopoietischer stammzellen
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes

Also Published As

Publication number Publication date
US5824304A (en) 1998-10-20
USRE40811E1 (en) 2009-06-30
JP3731892B2 (ja) 2006-01-05
CA2148712C (en) 2012-01-17
ATE150975T1 (de) 1997-04-15
ES2102196T3 (es) 1997-07-16
JPH08506091A (ja) 1996-07-02
US5695755A (en) 1997-12-09
DE69309487D1 (de) 1997-05-07
DK0670735T3 (da) 1997-07-28
US5843438A (en) 1998-12-01
EP0670735B1 (de) 1997-04-02
AU5727294A (en) 1994-06-08
JP2003277294A (ja) 2003-10-02
GR3023975T3 (en) 1997-10-31
AU689454B2 (en) 1998-04-02
CA2148712A1 (en) 1994-05-26
WO1994011027A1 (en) 1994-05-26
EP0670735A1 (de) 1995-09-13

Similar Documents

Publication Publication Date Title
DE69309487D1 (de) Peripheralisierung hämatopoietischer stammzellen
ES2130651T3 (es) Lipidos del tipo ceramida modificados con polietilenglicol y liposomas.
DE68929384T2 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
NO2014016I2 (no) Dimetylfumarat
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
GB9619691D0 (en) Antibodies against E-selection
ES2107762T3 (es) Utilizacion de un alquilester de glutation en una composicion cosmetica o dermatologica destinada al tratamiento por via topica del envejecimiento cutaneo.
DE3686525D1 (de) Hochfeste einkristall-superlegierungszusammensetzungen.
ES2122283T3 (es) Inhibicion del crecimiento capilar.
SE8402560L (sv) Farmaceutisk komposition
FI943728A (fi) Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia
ES2181501T3 (es) Composicion cosmetica.
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
EP0642507A4 (en) Catalytic antibodies against cocaine and methods of using and producing same.
GR82116B (de)
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
PT765398E (pt) Populacao de celulas enriquecedoras em progenitores mieloides e linfoides e metodos de as fazer e utilizar
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
BE1003463A4 (fr) Tensioactifs amphoteres contenant un oxyde d'alkylene.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BOARD OF REGENTS OF UNIVERSITY OF WASHINGTON, SEAT

8363 Opposition against the patent
8365 Fully valid after opposition proceedings